RT Journal Article
SR Electronic
T1 Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for Covid-19 Outpatients in Saudi Arabia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.16.20175752
DO 10.1101/2020.08.16.20175752
A1 Mohana, Abdulrhman
A1 Sulaiman, Tarek
A1 Mahmoud, Nagla
A1 Hassanein, Mustafa
A1 Alfaifi, Amel
A1 Alenazi, Eissa
A1 Radwan, Nashwa
A1 AlKhalifah, Nasser
A1 Elkady, Ehab
A1 Almohaizeie, Abdullah
A1 AboGazalah, Fouad
A1 AbdulKareem, Khaled
A1 AlGhofaili, Fahad
A1 Jokdar, Hani
A1 Alrabiah, Fahad
YR 2020
UL http://medrxiv.org/content/early/2020/08/17/2020.08.16.20175752.abstract
AB Background Healthcare systems globally has been challenged following the COVID-19 pandemic, since late 2019. Multiple approaches and strategies have been performed to relieve the pressure and support existing healthcare systems. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the National Healthcare System. Since the 5th of June 2020, 238 outpatient fever clinics were established across Saudi Arabia.Methods A cross-sectional study included 2,733 eligible patients subjected to MOH treatment protocol (hydroxychloroquine and zinc) and revisited the clinics within 3-7 days after treatment initiation. This study aimed to assess the safety outcome and reported adverse events from hydroxychloroquine use among suspected COVID-19 patients. The data was collected through an electronic link and cross-checked with that of the national database (Health Electronic Surveillance Network, HESN) and reports from the MOH Morbidity and Mortality (M&M) Committee.Results Majority of the cases were males (70.4%). Upon reassessing the studied participants within 3-7 days, 240 patients (8.8%) discontinued the treatment protocol because of the development of side effects (4.1%) and for non-clinical reasons in the remaining (4.7%). Medication side effects overall were reported among (6.7%) of all studied participants, including mainly cardiovascular adverse events (2.5%), followed by gastrointestinal (GI) symptoms (2.4%). No Intensive Care Unit (ICU) admission or death were reported among these patients.Conclusion In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is of an ongoing project at Saudi Arabia Ministry of Health. No external funding were obtained.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Saudi Arabia Ministry of Health IRB committee review, approved, and continuously audit this researchAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request